BLACK DIAMOND THERAPEUTICS

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small-molecule. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform namely, Mutation-Allostery-Pharmacology which is targeting mutations in cancer. Black Diamond focused on the discovery and development of precision medicines for cancer that is directed against a novel class of allosteric mutant oncogenes. The company targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. It is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.